Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

被引：13
|
作者：
Devlies, Wout [1 ,2 ]
Eckstein, Markus [3 ]
Cimadamore, Alessia [4 ]
Devos, Gaetan [1 ]
Moris, Lisa [1 ,2 ]
van den Broeck, Thomas [1 ]
Montironi, Rodolfo [4 ]
Joniau, Steven [1 ]
Claessens, Frank [2 ]
Gevaert, Thomas [5 ]
机构：
[1] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium
[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany
[4] Polytech Univ theMarche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60121 Ancona, Italy
[5] Univ Hosp Leuven, Dept Pathol, B-3000 Leuven, Belgium
来源：
CELLS | 2020年 / 9卷 / 11期
关键词：
prostate cancer; biomarker; targeted therapies; histology; mCRPC; androgen receptor; ANDROGEN-DEPRIVATION THERAPY; CIRCULATING TUMOR-CELLS; POZ PROTEIN SPOP; EMERGING MECHANISMS; RECEPTOR; EXPRESSION; MUTATIONS; GENE; TMPRSS2-ERG; INHIBITORS;
D O I：
10.3390/cells9112494
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
引用
收藏
页码：1 / 13
页数：13
相关论文
共 50 条
  • [31] Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
    LeVee, Alexis
    Lin, Ching Ying
    Posadas, Edwin
    Figlin, Robert
    Bhowmick, Neil A.
    Di Vizio, Dolores
    Ellis, Leigh
    Rosser, Charlos J.
    Freeman, Michael R.
    Theodorescu, Dan
    Freedland, Stephen J.
    Gong, Jun
    ONCOTARGETS AND THERAPY, 2021, 14 : 4819 - 4832
  • [32] Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
    Chen, William S.
    Aggarwal, Rahul
    Zhang, Li
    Zhao, Shuang G.
    Thomas, George, V
    Beer, Tomasz M.
    Quigley, David A.
    Foye, Adam
    Playdle, Denise
    Huang, Jiaoti
    Lloyd, Paul
    Lu, Eric
    Sun, Duanchen
    Guan, Xiangnan
    Rettig, Matthew
    Gleave, Martin
    Evans, Christopher P.
    Youngren, Jack
    True, Lawrence
    Lara, Primo N.
    Kothari, Vishal
    Xia, Zheng
    Chi, Kim N.
    Reiter, Robert E.
    Maher, Christopher A.
    Feng, Felix Y.
    Small, Eric J.
    Alumkal, Joshi J.
    EUROPEAN UROLOGY, 2019, 76 (05) : 562 - 571
  • [33] Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
    Fallara, Giuseppe
    Robesti, Daniele
    Raggi, Daniele
    Montorsi, Francesco
    Necchi, Andrea
    Cooperberg, Matthew R.
    Malavaud, Bernard
    Ploussard, Guillaume
    Martini, Alberto
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 52 : 40 - 43
  • [34] Targeting the androgen receptor in metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (03) : 329 - 332
  • [35] Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
    Menssouri, Naoual
    Poiraudeau, Loic
    Helissey, Carole
    Bigot, Ludovic
    Sabio, Jonathan
    Ibrahim, Tony
    Pobel, Cedric
    Nicotra, Claudio
    Ngo-Camus, Maud
    Lacroix, Ludovic
    Rouleau, Etienne
    Tselikas, Lambros
    Chauchereau, Anne
    Blanc-Durand, Felix
    Bernard-Tessier, Alice
    Patrikidou, Anna
    Naoun, Natacha
    Flippot, Ronan
    Colomba, Emeline
    Fuerea, Alina
    Albiges, Laurence
    Lavaud, Pernelle
    van de Wiel, Paul
    den Biezen, Eveline
    Wesseling-Rozendaal, Yvonne
    Ponce, Santiago
    Michiels, Stefan
    Massard, Christophe
    Gautheret, Daniel
    Barlesi, Fabrice
    Andre, Fabrice
    Besse, Benjamin
    Scoazec, Jean-Yves
    Friboulet, Luc
    Fizazi, Karim
    Loriot, Yohann
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4504 - 4517
  • [36] Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations
    Tsai, Alexander K.
    Kagalwalla, Sana
    Langer, Jenna
    Le-Kumar, Thuy
    Le-Kumar, Vikas
    Antonarakis, Emmanuel S.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (1-2) : 51 - 62
  • [37] The role of abiraterone in the management of metastatic castration-resistant prostate cancer
    Rawlinson, Alex
    Mohammed, Aza
    Beatty, John
    Bell, Richard
    Miller, Marek
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (04) : 429 - 437
  • [38] Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review
    Tian, Shengri
    Lei, Zhen
    Gong, Zuo
    Sun, Zhonghai
    Xu, Dongyuan
    Piao, Minhu
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [39] Management of Metastatic Castration-Resistant Prostate Cancer Recent Advances
    Mukherji, Deborah
    Eichholz, Andrew
    De Bono, Johann S.
    DRUGS, 2012, 72 (08) : 1011 - 1028
  • [40] Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer
    Kwan, Edmond M.
    Wyatt, Alexander W.
    PROSTATE, 2022, 82 : S25 - S36
12345